Considerations for CPX-351 in Acute Myeloid Leukemia
2 Visualizações
• 07/04/23
0
0
Embutir
administrator
Assinantes
Expert panelists Eunice Wang, MD; Harry Erba, MD, PhD; Alexander E. Perl, MD; and Jorge E. Cortes, MD, identify important considerations when treating acute myeloid leukemia with CPX-351, such as its toxicity profile and patient stratification.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários